List of Livalo drug patents

Livalo is owned by Kowa Co.

Livalo contains Pitavastatin Calcium.

Livalo has a total of 4 drug patents out of which 0 drug patents have expired.

Livalo was authorised for market use on 03 August, 2009.

Livalo is available in tablet;oral dosage forms.

Livalo can be used as adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia.

The generics of Livalo are possible to be released after 19 August, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993 KOWA CO Crystalline forms of pitavastatin calcium
Feb, 2024

(10 months from now)

US7022713 KOWA CO Hyperlipemia therapeutic agent
Feb, 2024

(10 months from now)

US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium
Aug, 2024

(1 year, 4 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent
Aug, 2024

(1 year, 4 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 16, 2022
Pediatric Exclusivity (PED) Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia

Dosage: TABLET;ORAL

How can I launch a generic of LIVALO before it's patent expiration?
More Information on Dosage

LIVALO family patents

16

United States

15

Japan

6

European Union

4

Taiwan, Province of China

4

China

2

Germany

2

Poland

2

Canada

1

Portugal

1

Slovenia

1

Korea, Republic of

1

Hong Kong

1

Australia

1

Denmark

1

Austria

1

Spain

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in